In-Person Access Only | 4.50 CME Credits
Please read:All programs remain free. Registrations will require a credit card as a cancellation hold. A fee of $99 will only be incurred in the event of a no-show or cancellation within 5 days without written confirmation to the Total Health Program Team. Industry representatives—defined as any individual who is employed by, contracted with, owns, or represents a drug, device, diagnostic, or other healthcare-related commercial entity, regardless of clinical credentials or licensure—are not permitted to attend Total Health events as general attendees. Members of industry must contact exhibits@totalhealthoncology.com
The First Annual DEBATING BREAST CANCER Symposium will take place January 22–23, 2027, in San Francisco, California. This first-of-its-kind educational forum brings together internationally recognized breast cancer experts for a series of engaging, evidence-based debates addressing the most controversial and practice-changing questions in breast oncology. Covering early-stage disease, metastatic breast cancer, and emerging future directions, faculty will present opposing viewpoints on evolving standards of care, novel therapeutics, biomarker-driven treatment strategies, clinical trial design, and the integration of cutting-edge technologies such as ctDNA and artificial intelligence. Designed to challenge conventional thinking and encourage thoughtful discussion, the symposium provides attendees with balanced perspectives, practical clinical insights, and actionable strategies to navigate the rapidly evolving breast cancer treatment landscape.
Conference Agenda
Friday, January 22, 2027
Program Chairs:
TBD
3:00 - 4:00 PM
Arrival, Networking, and Registration
4:00 - 5:30 PM
Breakout Focus Groups
5:30 - 6:30 PM
Networking Reception
7:00 - 9:00 PM
Faculty Dinner
Saturday, January 23, 2027
7:30 - 8:30 AM
Arrival, Breakfast, and Registration
8:30 - 8:45 AM
Welcome and Opening Remarks
8:45 - 10:15 AM
Early Stage Breast Debate
CDK4/6 Inhibitors in Early HR+/HER2− Disease: New Standard or Selective Use?
ctDNA in Early Breast Cancer: Ready for Clinical Prime Time?
Adjuvant therapy for Triple Negative Breast Cancer patients who achieve pathologic CR after neoadjuvant therapy
10:15 - 10:30 AM
Breakfast & Exhibits
10:30 AM - 12:00 PM
Advanced Stage Breast Debate
ADCs vs Chemotherapy: Has Conventional Chemotherapy Become Obsolete?
Comprehensive NGS for Every Metastatic Patient?
Sequencing in HR+/HER2− Disease: Are CDK4/6 Inhibitors Still the Center of the Universe?
12:00 - 12:45 PM
Lunch & Exhibits
12:45 - 1:45 PM
Future Directions in Breast Debate
Will ctDNA Replace Imaging in Surveillance?
The Future of Clinical Trials: AI enabled
1:45 - 3:30 PM
Breakout Focus Groups
3:30 PM
ADJOURN
Agenda Subject To Change. All times are PST..
-
Integrate new evidence into everyday clinical practice, thereby improving the quality of care being delivered to patients living with and beyond cancer.
Implement practice changes in a variety of treatment options for solid tumors, including lung, breast, melanoma, colorectal, ovarian, non-colorectal GI, and GU cancers
Stimulate innovative strategies for new and additional research related to treatment and prevention
Recognize the implications for practice change in both the academic and community practice settings
-
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Total Health. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Nurses (ANCC) Credit Designation
Amedco LLC designates this activity for a maximum of 7.50 ANCC contact hours.
Physicians (ACCME) Credit Designation
Amedco LLC designates this live activity for a maximum of 7.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacists and Pharmacy Technicians (ACPE) Credit Designation
Amedco LLC designates this activity for a maximum of 7.50 knowledge-based CPE contact hours.
NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 45 days of your participation in the activity to meet the deadline for submission to CPE Monitor.
American Board of Internal Medicine (ABIM) MOC Credit
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 7.50 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. You must request your certificate within 45 days of the activity to meet the deadline for submission to PARS.
-
Free registration for all healthcare providers
Expert sessions that present the most clinically relevant data, research, and clinical strategies
Enduring video content for watching at your leisure
Real-time discussion and debate
Networking with peers, colleagues, and medical professionals
Access to the latest industry information and resources
Catered meals through-out the program